Welcome to our dedicated page for TransCode Therapeutics news (Ticker: $RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TransCode Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TransCode Therapeutics's position in the market.
Rhea-AI Summary
TransCode Therapeutics receives FDA clearance to begin Phase 1/2 clinical trial with TTX-MC138 in patients with advanced solid tumors, aiming to evaluate safety and anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.69%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) reported financial results for 2023 and key business developments. The company advanced its lead therapeutic candidate, TTX-MC138, into clinical trials, raised over $25 million in equity financing, and signed strategic collaborations. Positive preliminary clinical results were reported, and key partnerships were formed to develop RNA therapeutics for cancer treatment. The company aims to initiate a Phase 1 clinical trial for TTX-MC138 in mid-2024, with a focus on advancing research and expanding collaborations in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. appoints Dr. Daniel Vlock, a seasoned medical oncologist with over 25 years of industry experience, as Chief Medical Officer. Dr. Vlock's extensive background includes pivotal roles in managing clinical trials and successful product developments in oncology, infectious diseases, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
Rhea-AI Summary
TransCode Therapeutics (NASDAQ: RNAZ) reports positive proof-of-concept studies in collaboration with Akribion Genomics for a potential cancer treatment involving CRISPR technology. The partnership aims to combine Akribion's G-dase E with TransCode's TTX delivery platform to target cancer cells effectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces Chief Scientific Officer Dr. Zdravka Medarova to present at RNA Leaders Europe Congress. The presentation will focus on TTX-MC138, a potential therapy for metastatic cancer, detailing preclinical and early clinical trial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the publication of a US Patent Application focusing on innovative cancer therapy using RNA therapeutics. The application targets RIG-I-like receptors to activate the immune system against cancer cells, potentially revolutionizing cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has received notice from the Nasdaq Stock Market LLC that it has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing. The company will be subject to a mandatory panel monitor through January 26, 2025. Additionally, the company was notified that it was not in compliance with the minimum bid price rule, and it must regain compliance by May 6, 2024, or be eligible for an additional 180 calendar day compliance period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces a co-research agreement with Debiopharm to explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer. The collaboration aims to test the development of new targeted nucleic acid delivery modalities, with the potential to revolutionize cancer research and treatment. TransCode's lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) has closed a public offering, raising $7.25 million in gross proceeds. The offering included 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a price of $1.22 per share. The company plans to use the net proceeds for product development activities, including clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) announces the pricing of a public offering of 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a combined public offering price of $1.22 per share. The warrants will have an exercise price of $1.22 per share and will expire three and one-half years from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.3%
Tags
TransCode Therapeutics, Inc.
Nasdaq:RNAZ
RNAZ Rankings
RNAZ Stock Data
6.23M
5.81M
0.15%
0.31%
0.69%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
BOSTON
About RNAZ
transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.